Selumetinib and Olaparib in Solid Tumors
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Malignant Neoplasm of Breast|Malignant Neoplasms of Digestive Organs|Malignant Neoplasms of Female Genital Organs|Malignant Neoplasms of Male Genital Organs|Malignant Neoplasms of Thyroid and Other Endocrine Glands
Interventions: DRUG: Selumetinib|DRUG: Olaparib
Sponsor: M.D. Anderson Cancer Center
Collaborators: AstraZeneca